A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer
- Interventions
- Registration Number
- NCT06203210
- Lead Sponsor
- Daiichi Sankyo
- Brief Summary
This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
- Detailed Description
The primary objective of this study is to assess whether treatment with I-DXd improves objective response rate (ORR) and prolongs overall survival (OS) compared with treatment of physician's choice among participants with relapsed SCLC.
The secondary objectives of the study are to further evaluate the efficacy/safety of I-DXd, health economics and outcome research measures (including patient reported outcomes), immunogenicity of I-DXd, B7-H3 protein expression, and characterize the pharmacokinetics of I-DXd.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 540
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Treatment of Physician's Choice (TPC) Amrubicin Participants randomized to receive topotecan, lurbinectedin, or amrubicin, as per investigator's choice and per locally approved label (indicated dose and frequency), until a treatment discontinuation criterion is met as specified in the protocol. Ifinatamab deruxtecan (I-DXd) Ifinatamab deruxtecan Participants randomized to receive 12 mg/kg I-DXd monotherapy on Day 1 of each 21-day cycle until unacceptable toxicity, progressive disease (PD), or withdrawal of consent as specified in the protocol. Treatment of Physician's Choice (TPC) Topotecan Participants randomized to receive topotecan, lurbinectedin, or amrubicin, as per investigator's choice and per locally approved label (indicated dose and frequency), until a treatment discontinuation criterion is met as specified in the protocol. Treatment of Physician's Choice (TPC) Lurbinectedin Participants randomized to receive topotecan, lurbinectedin, or amrubicin, as per investigator's choice and per locally approved label (indicated dose and frequency), until a treatment discontinuation criterion is met as specified in the protocol.
- Primary Outcome Measures
Name Time Method Number of Participants With Objective Response Rate Assessed by Blinded Independent Central Review Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 5 years Confirmed objective response rate (ORR) is defined as the sum of the complete response (CR) rate and partial response (PR) rate based on BICR by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1.
Overall Survival From the date of randomization to the date of death due to any cause, up to approximately 5 years
- Secondary Outcome Measures
Name Time Method Pharmacokinetic Parameter Maximum Concentration for I-DXd, Total Anti-B7-H3 Antibody, and MAAA-1181a Cycle 1 before infusion (BI), end of infusion EOI), and 3, 6, 24, 72, 168, 336, and 504 hours (hrs) post dose; Cycle 2 BI and EOI; Cycle 3 BI, EOI, and 6 hrs postdose; Cycles 4, 5, and every 2 cycles thereafter up to 5 years BI (each cycle is 21 days) Maximum concentration (Cmax) will be assessed using non-compartmental methods in participants randomized to the I-DXd group.
Pharmacokinetic Parameter Time to Maximum Concentration for I-DXd, Total Anti-B7-H3 Antibody, and MAAA-1181a Cycle 1 before infusion (BI), end of infusion EOI), and 3, 6, 24, 72, 168, 336, and 504 hours (hrs) post dose; Cycle 2 BI and EOI; Cycle 3 BI, EOI, and 6 hrs postdose; Cycles 4, 5, and every 2 cycles thereafter up to 5 years BI (each cycle is 21 days) Time to maximum concentration (Tmax) will be assessed using non-compartmental methods in participants randomized to the I-DXd group.
Number of Participants With Objective Response Rate Assessed by Investigator Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 5 years Confirmed objective response rate (ORR) is defined as the sum of the complete response (CR) rate and partial response (PR) rate based on investigator by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1.
Progression-free Survival As Assessed by Blinded Independent Central Review and Investigator Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 5 years PFS is defined as the time interval from the date of randomization to the date of disease progression as per BICR and investigator assessment or death due to any cause.
Duration of Response As Assessed by Blinded Independent Central Review and Investigator From the date of first documentation of confirmed response (CR or PR) to the first documentation of objective progression or to death due to any cause, whichever occurs first, up to approximately 5 years Duration of response (DoR) is defined as the time from the date of the first documentation of objective response (complete response \[CR\] or partial response \[PR\]) to the date of the first documentation of progressive disease (PD) or death. The DoR will be calculated for responding participants (PR or CR) only.
Disease Control Rate As Assessed by Blinded Independent Central Review and Investigator Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 5 years Disease control rate is defined as the proportion of participants who have achieved a best overall response of confirmed CR, confirmed PR, or SD (or non-CR/non-PD) by BICR and investigator assessment per RECIST v1.1.
Time to Response As Assessed by Blinded Independent Central Review and Investigator From the start date of study drug to the date of the first documentation of response (CR or PR) that is subsequently confirmed, up to approximately 5 years TTR is defined as the time from the date of randomization to the first documentation of objective tumor response (CR or PR) that is subsequently confirmed by BICR and investigator assessment .Time to response (TTR) will be calculated for confirmed responders only.
Change from Baseline in The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30 Baseline up to 5 years This 30-item questionnaire assesses global health status (GHS)/quality of life (QoL), subject functioning, and general cancer symptoms and has a recall period of one week. All scores for the EORTC QLQ-C30 instrument are linearly transformed to a 0 to 100 metric, where a higher score on GHS/QoL and functioning scales indicates a better outcome and a higher score for the symptom scales indicates worse outcomes.
Change from Baseline in The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 29 (EORTC QLQ-LC29) Baseline up to 5 years The LC29 is a self-reported 29-item questionnaire that measures SCLC-related symptoms and the side effects of treatments and has a recall period of one week. All scores range from 0 to 100, with a higher score indicating a worse outcome.
Overall Number of Participants With Treatment-emergent Adverse Events Following I-DXd Monotherapy Baseline up to 5 years TEAEs are assessed based on NCI CTCAE v5.0.
The Number of Participants Who Are Anti-Drug Antibody (ADA)-Positive At Any Time and Who Have A Treatment-emergent Anti-Drug Antibody Baseline up to 5 years The ADA prevalence, which is the percentage of participants who are ADA positive at any time point (baseline or post-baseline), as well as the ADA incidence, which is the proportion of participants having treatment-emergent ADA during the study period, will only be reported in participants receiving I-DXd.
Pharmacokinetic Parameter Area Under the Plasma Concentration-Time Curve for I-DXd, Total Anti-B7-H3 Antibody, and MAAA-1181a Cycle 1 before infusion (BI), end of infusion EOI), and 3, 6, 24, 72, 168, 336, and 504 hours (hrs) post dose; Cycle 2 BI and EOI; Cycle 3 BI, EOI, and 6 hrs postdose; Cycles 4, 5, and every 2 cycles thereafter up to 5 years BI (each cycle is 21 days) Area under the plasma concentration-time curve up to the last quantifiable time point (AUClast) and area under the plasma concentration-time curve dosing interval (AUCtau) will be assessed using non-compartmental methods in participants randomized to the I-DXd group.
Trial Locations
- Locations (230)
Highlands Oncology Group
🇺🇸Springdale, Arkansas, United States
Clinical Research Providence Medical Foundation
🇺🇸Fullerton, California, United States
UCLA Hematology-Oncology
🇺🇸Los Angeles, California, United States
Ucsf Mount Zion Medical Ctr
🇺🇸San Francisco, California, United States
University of Miami Hospital and Clinics Sylvester Comprehensive Cancer Center
🇺🇸Miami, Florida, United States
AdventHealth Orlando, Cancer Institute
🇺🇸Orlando, Florida, United States
H. Lee Moffitt Cancer Center and Research Institute, Inc
🇺🇸Tampa, Florida, United States
Rush University Medical Center
🇺🇸Chicago, Illinois, United States
Baptist Health Lexington
🇺🇸Lexington, Kentucky, United States
University of Maryland Medical Group
🇺🇸Baltimore, Maryland, United States
John Hopkins School of Medicine
🇺🇸Baltimore, Maryland, United States
Dana-Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Henry Ford Health System
🇺🇸Detroit, Michigan, United States
Mercy Clinic Oncology and Hematology Sindelar Cancer Center
🇺🇸Saint Louis, Missouri, United States
University of Nebraska Medical Center
🇺🇸Omaha, Nebraska, United States
Dartmouth-Hitchcock Medical Center
🇺🇸Lebanon, New Hampshire, United States
Astera Cancer Care
🇺🇸East Brunswick, New Jersey, United States
Meridian Health Systems
🇺🇸Neptune, New Jersey, United States
Montefiore Medical Center Prime
🇺🇸Bronx, New York, United States
Clinical Research Alliance, Inc
🇺🇸Lake Success, New York, United States
New York University Cancer Center - Laura and Isaac
🇺🇸New York, New York, United States
Mercy Medical Center
🇺🇸Canton, Ohio, United States
Oncology/Hematology Care Clinical Trials, Llc
🇺🇸Cincinnati, Ohio, United States
Providence Portland Medical Center
🇺🇸Portland, Oregon, United States
THE WEST CLINIC, PLLC dba West Cancer Center
🇺🇸Germantown, Tennessee, United States
Houston Methodist Cancer Center
🇺🇸Houston, Texas, United States
University of Texas Md Anderson Cancer Center
🇺🇸Houston, Texas, United States
Texas Oncology, P.A. - Tyler
🇺🇸Tyler, Texas, United States
Medical College of Wisconsin
🇺🇸Milwaukee, Wisconsin, United States
Ballarat Base Hospital
🇦🇺Ballarat, Australia
Flinders Medical Centre (Fmc)
🇦🇺Bedford Park, Australia
Chris O Brien Lifehouse
🇦🇺Camperdown, Australia
Sunshine Hospital
🇦🇺St Albans, Australia
St John of God Subiaco Hospital
🇦🇺Subiaco, Australia
Townsville Cancer Centre
🇦🇺Townsville, Australia
Princess Alexandra Hospital
🇦🇺Woolloongabba, Australia
Landeskrankenhaus Feldkirch
🇦🇹Feldkirch, Austria
Landesklinikum Krems
🇦🇹Krems, Austria
Kepler University Hospital
🇦🇹Linz, Austria
Wiener Gesundheitsverband Klinik Penzing
🇦🇹Wien, Austria
Klinik Floridsdorf
🇦🇹Wien, Austria
Cliniques Universitaires Saint-Luc
🇧🇪Bruxelles, Belgium
UZA
🇧🇪Edegem, Belgium
Jessa Ziekenhuis Hospital
🇧🇪Hasselt, Belgium
Chu de Liă Ge
🇧🇪Liege, Belgium
AZ DELTA
🇧🇪Roeselare, Belgium
Chu Ucl Namur
🇧🇪Yvoir, Belgium
Departmento de Pesquisa Clinica- Hospital de Amor de Barretos
🇧🇷Barretos, Brazil
Cepon - Centro de Pesquisas Oncolăgicas de Santa Catarina
🇧🇷FlorianĂłpolis, Brazil
Clínica de Neoplasias Litoral
🇧🇷ItajaĂ-, Brazil
Hospital São Lucas Da Pucrs
🇧🇷Porto Alegre, Brazil
Cepho Centro de Estudos E Pesquisas de Hematologia E Oncologia
🇧🇷Santo Andre, Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto
🇧🇷Sao Jose Rio Preto, Brazil
Hospital Benefică Ncia Portuguesa de Să O Paulo
🇧🇷São Paulo, Brazil
Hospital Alemão Oswaldo Cruz
🇧🇷São Paulo, Brazil
Icesp - Instituto Do Câncer Do Estado de São Paulo Octavio Frias de Oliveira
🇧🇷SĂŁo Paulo, Brazil
Hospital Sirio-Libanes
🇧🇷SĂŁo Paulo, Brazil
A. C. Camargo Cancer Center
🇧🇷SĂŁo Paulo, Brazil
William Osler Health System - Brampton Civic Hospital
🇨🇦Brampton, Canada
Cross Cancer Institute
🇨🇦Edmonton, Canada
Institut Universitaire de Cardiologie Et de Pneumologie de Quebec
🇨🇦Quebec City, Canada
Princess Margaret Cancer Center
🇨🇦Toronto, Canada
Cancercare Manitoba
🇨🇦Winnipeg, Canada
China-Japan Friendship Hospital
🇨🇳Beijing, China
Beijing Cancer Hospital
🇨🇳Beijing, China
Beijing Chest Hospital,Capital Medical University
🇨🇳Beijing, China
Jilin Province Tumor Hospital
🇨🇳Changchun, China
Hunan Cancer Hospital
🇨🇳Changsha, China
West China Hospital, Sichuan University
🇨🇳Chengdu Shi, China
Sichuan Cancer Hospital
🇨🇳Chengdu, China
Chongqing University Cancer Hospital
🇨🇳Chongqing, China
Harbin Medical University Cancer Hospital
🇨🇳Haerbin, China
The First Affiliated Hospital, College of Medicine, Zhejiang University
🇨🇳Hangzhou, China
Zhejiang Cancer Hospital
🇨🇳Hangzhou, China
The Second Affiliated Hospital of Nanchang University
🇨🇳Jiangxi, China
Shandong Cancer Hospital
🇨🇳Jinan, China
Linyi Cancer Hospital
🇨🇳Linyi, China
The Second Peoples Hospital of Neijiang
🇨🇳Neijiang, China
Yantai Yuhuangding Hospital
🇨🇳Shandong, China
Fudan University Shanghai Cancer Center
🇨🇳Shanghai, China
Liaoning Cancer Hospital & Institute
🇨🇳Shenyang, China
Tianjin Medical University Cancer Institute & Hospital
🇨🇳Tianjin, China
The Affiliated Cancer Hospital of Xinjiang Medical University
🇨🇳Urumqi, China
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
🇨🇳Wuhan, China
Huazhong University of Science and Technology - Tongji Medical College - Tongji Hospital Tjh
🇨🇳Wuhan, China
Hubei Cancer Hospital
🇨🇳Wuhan, China
The First Affiliated Hospital of Xiân Jiaotong University
🇨🇳Xi'an, China
Xiangyang Central Hospital
🇨🇳Xiangyang, China
Henan Cancer Hospital
🇨🇳Zhengzhou, China
Krajska Nemocnice Liberec A.S.
🇨🇿Liberec, Czechia
Fakultni Nemocnice Olomouc
🇨🇿Olomouc, Czechia
Fakultni Thomayerova Nemocnice
🇨🇿Praha 4, Czechia
Institut Sainte Catherine
🇫🇷Avignon Cedex 9, France
Chu Bordeaux
🇫🇷Bordeaux cedex, France
Centre Hospitalier Intercommunal de Cră Teil
🇫🇷Creteil Cedex, France
Institut Cœur Poumon CHU de Lille
🇫🇷Lille, France
Chu Limoges - Hopital Du Cluzeau
🇫🇷Limoges cedex, France
Centre Léon Bérard
🇫🇷Lyon, France
Assistance Publique-Hă"Pitaux de Marseille
🇫🇷Marseille, France
Hopital Arnaud de Villeneuve
🇫🇷Montpellier cedex 05, France
Institut Régional Du Cancer de Montpellier
🇫🇷Montpellier, France
Ch de Mulhouse - Hă"Pital Emile Muller
🇫🇷Mulhouse Cedex, France
Institut Curie - Site de Paris
🇫🇷Paris Cedex 05, France
Hopital Tenon
🇫🇷Paris, France
Chu Rennes - Hopital Pontchaillou
🇫🇷Rennes cedex 09, France
Chu Nantes - Hă"Pital Guillaume Et Renă Laă<Nnec
🇫🇷Saint Herblain, France
Institut de Cancerologie de La Loire
🇫🇷Saint-Priest-En-Jarez, France
Hă"Pital Foch
🇫🇷Suresnes Cedex, France
Institut Gustave Roussy
🇫🇷Villejuif, France
Evangelische Lungenklinik Berlin
🇩🇪Berlin, Germany
Helios Klinikum Erfurt
🇩🇪Erfurt, Germany
Universtitaetsklinikum Essen
🇩🇪Essen, Germany
Universitaetsklinikum Frankfurt Goethe-Universitaet
🇩🇪Frankfurt am Main, Germany
Krankenhaus Nordwest Gmbh
🇩🇪Frankfurt, Germany
Asklepios Fachkliniken Muenchen-Gauting
🇩🇪Gauting, Germany
Srh Wald-Klinikum Gera Gmbh
🇩🇪Gera, Germany
UNIVERSITATSKLINIKUM GIeBEN UND MARBURG GMBH
🇩🇪Giessen, Germany
Asklepios Klinik Harburg
🇩🇪Hamburg, Germany
Lki Lungenfachklinik Immenhausen
🇩🇪Immenhausen/Krs. Kassel, Germany
Staedtisches Krankenhaus Kiel
🇩🇪Kiel, Germany
Johannes Wesling Klinikum Minden
🇩🇪Minden, Germany
Pius-Hospital Oldenburg
🇩🇪Oldenburg, Germany
Universitaetsklinikum Ulm
🇩🇪Ulm, Germany
'Henry Dynant' Hospital Center
🇬🇷Athens, Greece
General Hospital of Athens of Chest Diseases 'Sotiria'
🇬🇷Athens, Greece
General Hospital of Athens Alexandra
🇬🇷Athens, Greece
University General Hospital "Attikon"
🇬🇷Chaidari, Greece
University General Hospital of Larissa
🇬🇷Larisa, Greece
General Hospital of Patra Agios Andreas
🇬🇷Patra, Greece
Metropolitan Hospital
🇬🇷Piraeus, Greece
St Luke'S Hospital
🇬🇷Thessaloniki, Greece
Semmelweis Egyetem
🇭🇺Budapest, Hungary
Orszagos Koranyi Pulmonologiai Intezet
🇭🇺Budapest, Hungary
Orszagos Onkologiai Intezet
🇭🇺Budapest, Hungary
Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz
🇭🇺Gyor, Hungary
Bács-Kiskun Vármegyei Oktatókórház
🇭🇺Kecskemet, Hungary
Istituto Tumori Giovanni Paolo Ii Irccs Ospedale Oncologico Bari
🇮🇹Bari, Italy
Humanitas Gavazzeni
🇮🇹Bergamo, Italy
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia (Presidio Spedali Civili)
🇮🇹Brescia, Italy
Azienda Ospedaliera Universitaria Policlinico - Vittorio Emanuele (Presidio Gaspare Rodolico)
🇮🇹Catania, Italy
Azienda Ospedaliero Universitaria Renato Dulbecco
🇮🇹Catanzaro, Italy
Istituto Nazionale Per La Ricerca Sul Cancro Di Genova
🇮🇹Genova, Italy
Ospedale San Raffaele
🇮🇹Milano, Italy
Fondazione Irccs Istituto Nazionale Dei Tumori
🇮🇹Milano, Italy
Ieo Istituto Europeo Di Oncologia
🇮🇹Milano, Italy
Azienda Socio Sanitaria Territoriale Di Monza (Presidio San Gerardo)
🇮🇹Monza, Italy
Azienda Ospedaliera Universitaria- Universită Degli Studi Della Campania  Luigi Vanvitelliâ
🇮🇹Napoli, Italy
Azienda Ospedaliero Universitaria Di Parma
🇮🇹Parma, Italy
Azienda Ospedaliera Di Perugia Ospedale S. Maria Della Misericordia
🇮🇹Perugia, Italy
Istituto Nazionale Tumori Regina Elena Irccs
🇮🇹Roma, Italy
Istituto Clinico Humanitas
🇮🇹Rozzano, Italy
Centro Ricerche Cliniche Di Verona S.R.L.
🇮🇹Verona, Italy
National Cancer Center Hospital
🇯🇵Chuo-ku, Japan
Kyushu University Hospital
🇯🇵Fukuoka, Japan
Kansai Medical University Hospital
🇯🇵Hirakata-shi, Japan
National Cancer Center Hospital East
🇯🇵Kashiwa, Japan
The Cancer Institute Hospital of Jfcr
🇯🇵Koto-ku, Japan
National Hospital Organization Shikoku Cancer Center
🇯🇵Matsuyama, Japan
Okayama University Hospital
🇯🇵Okayama, Japan
Kindai University Hospital
🇯🇵Osaka-Sayama, Japan
Kitasato University Hospital
🇯🇵Sagamihara, Japan
National Hospital Organization Hokkaido Cancer Center
🇯🇵Sapporo, Japan
Shizuoka Cancer Center
🇯🇵Sunto-gun, Japan
Osaka Medical and Pharmaceutical University Hospital
🇯🇵Takatsuki, Japan
Wakayama Medical University Hospital
🇯🇵Wakayama, Japan
Chungbuk National University Hospital
🇰🇷Cheongju, Korea, Republic of
Kyungpook National University Chilgok Hospital
🇰🇷Daegu, Korea, Republic of
Seoul National University Bundang Hospital
🇰🇷Seongnam-si, Korea, Republic of
Severance Hospital, Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
The Catholic University of Korea, St. Vincent'S Hospital
🇰🇷Suwon-si, Korea, Republic of
Ajou University Hospital
🇰🇷Suwon, Korea, Republic of
Netherlands Cancer Institute
🇳🇱Amsterdam, Netherlands
Maastricht University Medical Center
🇳🇱Maastricht, Netherlands
Jeroen Bosch Ziekenhuis
🇳🇱s Hertogenbosch, Netherlands
Etz Elisabeth
🇳🇱Tilburg, Netherlands
Centrum Onkologii Im. Prof. F. Lukaszczyka W Bydgoszczy
🇵🇱Bydgoszcz, Poland
Instytut Centrum Zdrowia Matki Polki
🇵🇱Lodz, Poland
Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy
🇵🇱Otwock, Poland
Szpital Specjalistyczny W Prabutach
🇵🇱Prabuty, Poland
Provita Prolife
🇵🇱Tomaszow Mazowiecki, Poland
Centro Hospitalar E Universită Rio de Coimbra E.P.E.
🇵🇹Coimbra, Portugal
Hospital Da Senhora Da Oliveira Guimară Es
🇵🇹Guimarães, Portugal
Hospital Da Luz
🇵🇹Lisboa, Portugal
Centro Hospitalar de Lisboa Norte, E.P.E. - Hospital Pulido Valente
🇵🇹Lisboa, Portugal
Centro Hospitalar Do Porto, E.P.E. - Hospital de Santo António
🇵🇹Porto, Portugal
Institutul Oncologic 'Prof. Dr. Ion Chiricuta' Cluj Napoca
🇷🇴Cluj Napoca, Romania
S.C Radiotherapy Center Cluj S.R.L
🇷🇴Comuna Floresti, Romania
S.C Centrul de Oncologie Sfantul Nectarie Craiova
🇷🇴Craiova, Romania
S.C. Sigmedical Services Srl
🇷🇴Suceava, Romania
Hospital Clinic de Barcelona
🇪🇸Barcelona, Spain
Hospital de La Santa Creu I Sant Pau
🇪🇸Barcelona, Spain
Hospital Universitari Vall D'Hebron
🇪🇸Barcelona, Spain
Hospital Universitario Reina Sofia
🇪🇸Cordoba, Spain
Hospital Universitario Ciudad de Jaen
🇪🇸Jaen, Spain
Hospital de Especialidades de Jerez de La Frontera
🇪🇸Jerez De Frontera, Spain
Ico L'Hospitalet - Hospital Duran I Reynals
🇪🇸L'Hospitalet de Llobregat, Spain
Complejo Hospitalario Universitario Insular Materno-Infantil
🇪🇸Las Palmas de Gran Canaria, Spain
Hospital General Universitario Gregorio Marañon
🇪🇸Madrid, Spain
Hospital Universitario Ramon Y Cajal
🇪🇸Madrid, Spain
Hospital Universitario Fundacion Jimenez Diaz
🇪🇸Madrid, Spain
Hospital Universitario 12 de Octubre
🇪🇸Madrid, Spain
Hospital Universitario La Paz
🇪🇸Madrid, Spain
Hospital Regional Universitario de Malaga
🇪🇸Malaga, Spain
Hospital Universitario Virgen Macarena
🇪🇸Sevilla, Spain
Hospital Universitario Virgen Del Rocio
🇪🇸Sevilla, Spain
Hospital Universitario Nuestra Señora de Valme
🇪🇸Sevilla, Spain
Inselspital - Universitaetsspital Bern
🇨🇭Bern, Switzerland
Kantonsspital St. Gallen
🇨🇭St. Gallen, Switzerland
Hfr Fribourg/Kantonsspital Fribourg
🇨🇭Villars-sur-Glâne, Switzerland
Kaohsiung Medical University Chung-Ho Memorial Hospital
🇨🇳Kaohsiung City, Taiwan
China Medical University Hospital
🇨🇳Taichung, Taiwan
Taichung Veterans General Hospital
🇨🇳Taichung, Taiwan
National Cheng Kung University Hospitalx
🇨🇳Tainan, Taiwan
National Taiwan University Cancer Centre
🇨🇳Taipei, Taiwan
Taipei Medical University Hospital
🇨🇳Taipei, Taiwan
Taipei Veterans General Hospital
🇨🇳Taipei, Taiwan
Chang Gung Memorial Hospital
🇨🇳Taoyuan County, Taiwan
Dr. Abdurrahman Yurtaslan Oncology Teaching and Research Hospital
🇹🇷Ankara, Turkey
Ankara City Hospital
🇹🇷Ankara, Turkey
Dicle University, Medical Faculty
🇹🇷Diyarbakir, Turkey
Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty
🇹🇷Istanbul, Turkey
Medipol University Medical Faculty
🇹🇷Istanbul, Turkey
Goztepe Prof. Dr. Suleyman Yalcin City Hospital
🇹🇷Istanbul, Turkey
Izmir Medicalpark Hospital
🇹🇷Izmir, Turkey
Birmingham Heartlands Hospital
🇬🇧Birmingham, United Kingdom
St James'S University Hospital
🇬🇧Leeds, United Kingdom
Churchill Hospital
🇬🇧Oxford, United Kingdom